跳到正文
原文
Scott Gottlieb, MD 🇺🇸· @ScottGottliebMD · X·· 26 天前精选AI 评分82
AI 导读

ESMO26数据确认,Moderna与默沙东的个体化mRNA癌症疫苗在黑色素瘤试验中达到关键终点,相比标准治疗将疾病复发降低42%。前FDA局长Scott Gottlieb指出,该疫苗组每位患者接受的产品均不相同,新抗原来自各自肿瘤测序,FDA没有单一活性序列可供审评,IND预先规定了产品对每位患者的变化方式。

推荐理由

材料同时给出个体化新抗原疫苗的疗效数据与监管审评方式,读者可据此理解这类疗法的双重特殊性。

正文

A watershed for FDA regulation. Every patient on the vaccine arm got a different product, with neoantigens chosen from sequencing of each person's own tumor. So FDA had no single active sequence to review. The IND pre-specified how the product would change for each patient.

引用Adam Feuerstein ✡️@adamfeuerstein
#ESMO26 embargo lifted following breach. Detailed data confirm Moderna $MRNA and Merck $MRK cancer vaccine met key endpoints in melanoma trial Personalized mRNA therapy reduced disease recurrence by 42% compared to standard treatment https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/
在 X 查看被引用的帖子

来源:Scott Gottlieb, MD 🇺🇸 · x.com